Oncolytics Biotech

1. GOBLET Cohort 4 anal cancer2H 2026GOBLET Cohort 4 anal cancer, 2H 2026, notable
2. Anal cancer pivotal start2H 2026Anal cancer pivotal start, 2H 2026, routine
3. REO 033 Part A interimyear-end 2026REO 033 Part A interim, year-end 2026, major
4. Revolution Medicines RAS(ON) colorectal strategy4Q 2026Revolution Medicines RAS(ON) colorectal strategy, 4Q 2026, routine
5. RAS-inhibitor combination preclinical readoutfall or winter of 2026RAS-inhibitor combination preclinical readout, fall or winter of 2026, notable
6. REO 033 Part B trial1Q 2027REO 033 Part B trial, 1Q 2027, notable
7. GOBLET Cohort 5 pancreatic interim1H 2027GOBLET Cohort 5 pancreatic interim, 1H 2027, notable
8. Common shares listing updateJan 19, 2027Common shares listing update, Jan 19, 2027, notable
9. Zanzalintinib plus atezolizumab Exelixis PDUFAMar 3, 2027Zanzalintinib plus atezolizumab Exelixis PDUFA, Mar 3, 2027, material
10. REO 033 toplineAug 30, 2027REO 033 topline, Aug 30, 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.